.jpeg)
Emcure partners with Roche to improve access to life-saving nephrology and transplant treatments in India. The collaboration expands care for CKD, anemia, and organ transplants.
Eli Lilly's tirzepatide holds premium pricing in India ahead of March 2026 generics rush. With explosive sales and stronger efficacy than competitors, the company sees room for both branded and low-cost options.
Eli Lilly and Company (India) has launched the next phase of its obesity awareness campaign, using films led by well-known personalities to shift the focus from blame to science and encourage doctor-led care.
Novo Nordisk has signed a $2.1 billion deal with Vivtex to develop an oral obesity drug platform, aiming to turn injectable weight-loss treatments into easy-to-take pills and expand patient access worldwide.
Shilpa Medicare has signed a strategic licensing agreement with SteinCares to commercialize a biosimilar across Latin America, strengthening its biologics portfolio and expanding its presence in emerging markets.
Lupin has secured European Commission approval for its biosimilar ranibizumab, marking a major step in expanding access to advanced eye care treatments across the European Union.
Johnson & Johnson has secured FDA approval for a monthly dosing schedule of RYBREVANT FASPRO, marking a major step forward in first-line treatment for EGFR-mutated advanced non-small cell lung cancer.
Novartis reported positive Phase III RemIND trial results for remibrutinib in chronic inducible urticaria, showing higher complete response rates than placebo and moving closer to the first targeted therapy for CIndU.
In an exclusive interaction with Thiruamuthan, Assistant Editor at India Pharma Outlook, Shishir Agarwal, President and Managing Director, Terumo India, discusses how MedTech companies are adapting their products and strategies to meet the growing de
.png)
The USFDA has completed its inspection of Enzene’s manufacturing unit in Chakan, Pune, issuing six procedural observations with no data integrity issues. The outcome strengthens the company’s compliance standing in regulated markets.
, CDSCO.jpg)